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Abstract. 
Purpose. The aim of this study is to assess the effect of PTH on Wnt10b production by 
immune system cells in humans. We assessed both the effect of intermittent PTH 
administration (iPTH) and of chronic PTH hyper secretion in primary hyperparathyroidism 
(PHP). 
Methods. Eighty-two women affected by post-menopausal osteoporosis were randomly 
assigned to treatment with calcium and vitamin D alone (22) or plus 1-84 PTH (42), or intra 
venous ibandronate (18). Wnt10b production by unfractioned blood nucleated cells and by 
T, B cells and monocytes was assessed by real time RT-PCR and ELISA at baseline, 3, 6, 
12 and 18 months of treatment.  
The effect of chronic elevation of PTH was evaluated in 20 patients affected by PHP at 
diagnosis and after surgical removal of parathyroid adenoma. 
WNT10b from both osteoporotic and PHP patients was compared to healthy subjects 
matched for age and sex. 
Results. iPTH increases Wnt10b production by T cells, whereas PHP does not. After 
surgical restoration of normal parathyroid function, WNT10b decreases, although it is still 
comparable with healthy subjects level. Thus chronic elevation of PTH does not 
significantly increase WNT10b production as respect to control. 
Conclusions. This is the first work showing the effect of both intermittent and chronic PTH 
increase on Wnt10b production by immune system cells. We suggest that, in humans, T 
cells amplified the anabolic effect of PTH on bone, by increasing Wnt10b production, 
which stimulates osteoblast activity.  
Key words: osteoporosis, primary hyperparathyroidism, PTH, Wnt10b, T cells, immune 
system. 
Mini Abstract. 
We evaluated the effect of PTH on Wnt10b production by immune system cells in humans. 
We showed that bone anabolic effect of intermittent PTH treatment may be amplified by T 
cells through increased production of Wnt10b. Chronic increase in PTH as in primary 
hyperparathyroidism does not increase Wnt10b expression.  
INTRODUCTION. 
Parathyroid hormone (PTH) regulates calcium and phosphate homeostasis and has 
profound effects on bone turnover. PTH chronic increase, as in primary or secondary 
hyperparathyroidism, has catabolic effects on bone, causes bone loss and increases 
fracture risk [1]. In contrast, intermittent PTH injection, has anabolic effects on bone [2] 
and prevents fragility fractures, indeed intermittent PTH is currently used for the treatment 
of post-menopausal osteoporosis [3,4].  
The PTH receptor (PPR) is mainly expressed in bone and kidney, but its expression has 
also been reported in other tissues where it likely reflects the local paracrine role of PTH 
related protein [5-7]. In bone, PPR is expressed in osteoclasts [8] and mainly in cells of 
osteoblastic lineage as osteocytes [9]. A recent work by Saini et al [9] suggests that 
osteocytes are necessary for intermittent PTH anabolic effects. Treatment with intermittent 
PTH activates Wnt signalling pathway in osteoblast by suppressing Sclerostin production 
by osteocytes [10-16]. 
PPR is also expressed by T cells [17], which are required for intermittent PTH to exert its 
bone anabolic effect as recently demonstrated in mice [17-19]. The bone anabolic 
response to intermittent PTH is blunted in the absence of T cells and is restored by 
adoptive transfer of these cells [17,18]. T cells mediate intermittent PTH anabolic effect on 
bone through the up-regulation of Wnt10b on their surface [18]; Wnt10b interacts with 
osteoblasts up-regulating Wnt pathway, and induces bone formation.  
Unlike intermittent PTH, continuous PTH infusion, a condition that mimics primary 
hyperparathyroidism (PHP) in humans, doesn’t affect Wnt10b expression by T cells in 
mice [17,18], whereas in humans no data are available. 
Here we show that PTH affects Wnt10b production by immune system cells in humans, 
potentially explaining its anabolic effect. 
 
MATERIALS AND METHODS 
Patients. 
The study was approved by the Ethical Committee of the A.O.U. Città della Salute e della 
Scienza - A.O. Ordine Mauriziano - A.S.L. TO1, Turin Italy and informed consent was 
obtained from all participants.  The study population was recruited from the patients of 
A.O.U. Città della Salute e della Scienza, Turin Italy and healthy volunteers.  The study 
included patients affected by post-menopausal osteoporosis and patients affected by 
primary hyperparathyroidism (PHP). 
 
Post-menopausal osteoporosis. 
Eighty-two women affected by post-menopausal osteoporosis without fractures were 
randomly allocated to treatment with: 
i. intermittent PTH (PTH 1-84 100 mcg/day s.c. -Preotact ®, kindly provided by 
Nycomed-plus calcium 1200 mg/day and colecalcipherol 800 UI/day, referred to 
hereafter as iPTH), 42 patients,  
ii. calcium and vitamin D 1200 mg/day and colecalcipherol 800 UI/day (referred to 
hereafter as calcium and vitamin D), 22 patients 
iii. intravenous ibandronate 3mg every 3 months, plus calcium and vitamin D (referred 
to hereafter as IB), 18 patients. 
This is a parallel, randomized controlled, open label, trial (registered as PTH1-84 EudraCT 
2009-012397-12). The randomization was done by computer generated tables to allocate 
treatments. Randomization was done by the principal investigator, patients were enrolled 
by participants in the study, lab measurement and statistical analyses were done in blind 
to treatment. 
Patients affected by secondary osteoporosis or taking drugs active on bone metabolism 
were not considered eligible for the study. 
Blood samples from patients were collected at baseline and after 3, 6, 12 and 18 months 
of treatment.  
Primary hyperparathyroidism. 
We enrolled in the study 20 patients (16 women and 4 men) affected by PHP, none of 
them were affected by diseases affecting bone health other than PHP. Subjects with 
secondary hyperparathyroidism, severe vitamin D deficiency, chronic renal disease 
(GFR<60) and any other condition known to affect PTH levels were excluded. 
The diagnosis of PHP was established on the finding of elevated circulating levels of 
calcium and PTH in at least 2 instances and the presence of normal renal function.  PHP 
patients were subjected to parathyroidectomy and restoration of normal parathyroid 
function was demonstrated by the finding of normal serum PTH and calcium levels 1 




Two groups of healthy subjects were enrolled as controls for post-menopausal women (31 
healthy post-menopausal women) and for PHP patients (42 healthy men and women in 
post-menopausal period or in fertile age). Patients and controls were matched for sex, age 
and years since menopause. 
 
The study design is summarized in figure 1. The demographic characteristics of the study 
population are shown in table 1.  
Measurements of Wnt 10b mRNA. 
Wnt10b mRNA was measured in unfractioned peripheral blood nucleated cells in 
osteoporotic patients, in PHP and in healthy controls. Unfractioned peripheral blood 
nucleated cells were obtained by red blood cells lyses, the obtained cells were frozen at -
80°C until RNA extraction. In 36 osteoporotic patients (18 treated with iPTH and 18 with 
IB) T cells, B cells and monocytes were separated by immunomagnetic beads separation 
(Stemcells Technology) to evaluate which cell produces Wnt10b (Fig.1).  
 
Real-Time PCR (RT-PCR) was used to evaluate Wnt10b expression. RNA was isolated 
using TRIzol reagent (Ambion, Huntingdon, UK), chloroform extraction, and subsequent 
isopropanol precipitation according to the manufacturer’s protocol. One µg of RNA was 
converted up to single-stranded cDNA by the High Capacity cDNA Reverse Transcription 
Kit (Applied-Biosystems). RT-PCR was performed with IQ SYBR Green Supermix 
(BIORAD). The housekeeping control gene was β-Actin and gene expression was 
quantified through 2-∆∆Ct method. The primers used were:  
5’- CCATGACATGGACTTTGGAGAG -3’ (forward), 5’- CTGGAATCCAAGAAATCCCG -3’ 
(reverse) for Wnt10b and 5’- CCTAAAAGCCACCCCACTTCT -3’ (forward) and 5’- 
CACCTCCCCTGTGTGGACTT -3’ (reverse) for β-Actin. 
Protein detection. 
Wnt10b protein was measured on cell lysates by ELISA technique (USCN Life Science) 
after correction for total amount of protein.  
 
Statistical analyses. 
Wnt10b values were not normally distributed according to kurtosis normality test, hence 
the effect of treatment on its expression was evaluated by repeated measure tests, after 
logarithmic transformation. Wnt10b mRNA levels were analysed by Mann Whitney (healthy 
controls vs. osteoporotic or PHP) and Wilcoxon matched pairs signed rank tests (PHP vs. 
PHP after surgery and different cell types). 
The sample size provided an 80% power, assuming a two-sided significance level of 0.05, 
to detect differences in Wnt10b of 3 fold, according with the results obtained in mice [18]. 
The statistical analyses was performed through SPSS 21.0 and graphs were designed 
through Prism Graph Pad 6.0. . 
 
RESULTS. 
Osteoporosis does not affect Wnt10b production by blood nucleated cells. 
To evaluate whether Wnt10b expression was decreased in osteoporosis, we compared its 
expression in unfractioned blood nucleated cells from osteoporotic patients and healthy 
women, matched for age and post-menopausal period. Wnt10b was not significantly 
different between patients and controls (Fig.2 A), suggesting that it is not involved in the 
pathogenesis of post-menopausal osteoporosis. 
 
iPTH increases Wnt10b production by T cells. 
Treatment with iPTH in osteoporotic women increases Wnt10b gene expression in 
peripheral blood nucleated cells, whereas calcium and vitamin D alone do not (Fig.2B). In 
particular Wnt10b increases of approximately 21 fold after 6 months of treatment and 
returned to baseline values after 18 months (Fig.2B). 
Wnt10b protein level, detected by ELISA, confirmed an increase of Wnt10b production 
during treatment with iPTH (Fig.2C), according to the RT-PCR results. The increase in 
Wnt10b mimics the observed rise in bone alkaline phosphatase (BAP, Fig.2D), that is a 
well-known bone formation marker. 
The analyses of separated T, B cells and monocytes as compared to unfractioned blood 
nucleated cells revealed that T cells are the main responsible for Wnt10b expression in 
osteoporotic patients without treatment, whereas B cells and monocytes only express a 
small amount of this molecule (Fig. 3 A). Further evaluation of T cells during iPTH 
treatment compared to IB reveals that the increase of Wnt10b expression depend on 
iPTH, indeed IB does not induce any significant variation (Fig 3 B). B cells and monocytes 
do not increase Wnt10b expression during treatment (Fig. 3 C and D). 
 
Chronic elevation of PTH did not increase Wnt10b expression. 
Wnt10b was not increased in unfractioned peripheral blood nucleated cells from patients 
affected by PHP compared to healthy controls (Fig. 4), nevertheless surgical restoration of 
normal parathyroid function decreased Wnt10b expression of about 36%.  
Even though surgical intervention decreased Wnt10b, its expression remain not 
significantly different as respect to healthy controls (Fig.4).  
All the surgical intervention were completely successful as demonstrated by the fall in PTH 




This study explores the effect of iPTH and PHP on Wnt10b production by T cells in 
humans we show that T cells are the main producers of Wnt10b amongst peripheral blood 
nucleated cells, and Wnt10b expression increases during iPTH treatment. These data 
suggest that T cells may mediate the anabolic action of iPTH in humans as they do in mice 
[17,18]. According to this hypothesis, literature data derived from animal models report that 
the anabolic activity of iPTH depends on T cells, which increase the expression of Wnt10b. 
[17,18]. Indeed, treatment with iPTH in mice stimulates T cell production of Wnt10b, that 
increases osteoblastogenesis. T cell-deficient mice or mice with T cell-knock out for 
Wnt10b display a blunted bone anabolism after treatment with iPTH [17].  
The analysis of Wnt10b expression in peripheral blood nucleated cells, at different time 
during iPTH treatment, allows us to create a Wnt10b curve that reveals an increase in its 
expression that is maximal 6 months after treatment. This increase was not observed in 
patients treated with calcium and vitamin D alone. The Wnt10b curve in response to iPTH 
mimics the well-known bone anabolic markers curve [3,4], confirming Wnt10b role in 
mediating iPTH anabolic action.  
Differently from iPTH, chronic elevation of PTH, as in PHP, does not increase Wnt10b 
expression. However, one month after surgical intervention, Wnt10b expression results 
significantly decreased, but comparable to healthy subjects. This result may depend on the 
small size of the cohort analyzed, but we speculate a possible effect of chronic elevation in 
PTH on Wnt10b that is not sufficient to increase it above normal range. To support this 
hypothesis, literature data report that chronic elevation of PTH in PHP modulates Wnt 
signaling pathway also by suppressing SOST in humans [20, 21] as well as in mice [22]. 
This observation may explain the anabolic effect on trabecular bone of PHP, indeed PHP 
preferentially involves cortical bone with preservation of cancellous areas, as 
demonstrated by histomorphometric analysis. In particular, the majority of patients with 
PHP showed reductions in cortical width, whereas the cancellous compartment of the 
bone biopsy specimen showed greater than average values for trabecular bone volume, 
trabecular number, connectivity and separation, indicating preservation of this bone 
compartment in most patients with PHP [23-26]. Here we describe a decrease in Wnt10b, 
after surgical restoration of normal parathyroid function, which may partially explain the 
anabolic effect of PHP on trabecular bone.  
Our study has a number of strengths: to our knowledge, this work represents the first study 
in humans to evaluate the effect of PTH on peripheral blood nucleated cells with particular 
regards to T cells. In addition, we attempted to do so without in vitro culture of the cells, 
which could substantially alter their gene expression and other characteristics. Patients 
and controls have been carefully matched for potential confounders and randomized to 
different treatment group. However one major limitation of our work is the small sample 
size especially of PHP cohort.  
 
In conclusion this study reports that PTH induces an increase of Wnt10b production by T 
cells in humans. Thus, our data suggest that T cells amplify the anabolic effect of PTH on 
bone.  
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Table 1. A Characteristics of osteoporotic patients and healthy controls.  
B Characteristics of PHP and healthy controls. 
Mean and standard deviations are shown for continuous variables, % for non-continuous 
one. P values were calculated by ANOVA one-way for continuous variable and by χ2 for 
non-continuous one. 
 
A          Post-menopausal osteoporosis 




IB none  
Patients (n) 42 22 18 31  
Women (%) 100% 100% 100% 100%  
Men (%) 0% 0% 0% 0%  
Age (yrs) 68.1±9.5 66.6±6.2 64.7±9.2 69±15.2 0.263 
Years since 
menopause 
18.6±10 14.8±9.3 17.7±10 17.0±10.6 0.186 
 
B                                                                  PHP 
 PHP Controls p value 
Patients (n) 20 42  
Women (%) 80 70 0.366 
Women in after 
menopause (%) 
56 47 0.191 
Men (%) 20 40 0.366 
Age (yrs) 57.3±15.4 50.5±21.5 0.214 
Years since 
menopause 
16±9.4 20.5±14.7 0.400 
 
FIGURES. 
Figure 1. The diagram shows the study design: the number of patients in each group and 












Figure 2. Wnt 10b expression in osteoporosis and during treatment. 
A. Levels (Median mean ± SE) of Wnt10b mRNA in healthy controls (n = 31) and 
osteoporotic subjects (n = 46). Data were analysed by Mann Whitney  as the data were 
not normally distributed according to the kurtosis normality test. 
B. Wnt10b mRNA fold change versus baseline in osteoporotic patients treated with 
iPTH (n=21) or calcium and vitamin D (n=20). Data were analysed by multiple 
measurement test after logarithmic transformation, as the data were not normally 
distributed according to the kurtosis normality test. 
C. Wnt10b protein production by unfractioned blood nucleated cells in osteoporotic 
patients treated with iPTH (n=21) or calcium and vitamin D (n=20). Data were analysed by 
Multiple measurement test after logarithmic transformation, as the data were not normally 
distributed according to the kurtosis normality test. 
D. Serum BAP in osteoporotic patients treated with iPTH (n=21) or calcium and vitamin 
D (n=20). Data were analysed by multiple measurement test. 
 
Figure 3. Wnt 10b expression by T cells. 
A. Wnt10b mRNA expression relative to unfractioned blood nucleated cells (median 
mean ± SE) in monocytes, T and B cells from osteoporotic patients without treatment (n = 
36). Data were analysed by Wilcoxon matched pairs signed rank test as the data were not 
normally distributed according to the kurtosis normality test. 
B. T cells Wnt10b mRNA fold change versus baseline in osteoporotic patients treated 
with iPTH (n=18) or IB (n=18). Data were analysed by multiple measurement test after 
logarithmic transformation, as the data were not normally distributed according to the 
kurtosis normality test. 
C. B cells Wnt10b mRNA fold change versus baseline in osteoporotic patients treated 
with iPTH (n=18) or IB (n=18). Data were analysed by multiple measurement test after 
logarithmic transformation, as the data were not normally distributed according to the 
kurtosis normality test. 
D. Monocytes Wnt10b mRNA fold change versus baseline in osteoporotic patients 
treated with iPTH (n=18) or IB (n=18). Data were analysed by multiple measurement test 
after logarithmic transformation, as the data were not normally distributed according to the 








Figure 4. Wnt 10b expression in PHP. Levels (Median mean ± SE) of Wnt10b mRNA in 
healthy controls (n = 42) and PHP before (n = 20) and after parathyroidectomy (n = 20). 
Data were analysed by Mann Whitney (healthy controls vs. PHP) and Wilcoxon matched 
pairs signed rank tests (PHP vs. PHP after surgery) as the data were not normally 
distributed according to the kurtosis normality test. 
 
 
